Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Skyrizi is a prescription medication that is used for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It’s also used as a treatment for active psoriatic arthritis or moderately to severely active Crohn’s disease in adults.
Skyrizi, an interleukin-23 antagonist, works to prevent the release of inflammatory chemicals.
Skyrizi comes in a subcutaneous injection and is available in prefilled pens, syringes, or cartridges in the following strengths:
Fact Table |
|
Formula |
C6476H9992N1720O2016S44 |
License |
US DailyMed, EU EMA, US FDA |
Bioavailability |
24%-63% |
Legal status |
Rx-Only |
Chemical Name |
risankizumab-rzaa |
Elimination half-life |
approximately 28 days |
Dosage (Strength) |
150 mg/mL single-dose prefilled pen 75 mg/0.83 mL single-dose prefilled syringe 150 mg/mL single-dose prefilled syringe 180 mg/1.2 mL single-dose prefilled cartridge 360 mg/2.4 mL single-dose prefilled cartridge |
Pregnancy |
Consult doctor |
Brands |
Skyrizi |
Protein binding |
Unknown |
PubChem CID |
363669765 |
MedlinePlus |
a619035 |
ChEBI |
Not Assigned |
ATC code |
L04AC18 |
DrugBank |
DB14762 |
KEGG |
D11052 |
Routes of administration |
Subcutaneous injection |
Follow your doctor’s instructions on injecting Skyrizi. Talk to your doctor or pharmacist about any questions or concerns you may have about the medication.
Each patient’s Skyrizi dose and duration of treatment is based on their condition. Your doctor will teach you how to properly inject Skyrizi as well as tell you how much medication should be injected and how long your treatment will be.
A humanized immunoglobulin G1 monoclonal antibody, risankizumab-rzaa, is contained in Skyrizi. Skyrizi also contains inactive ingredients; a full list can be found in the package insert.
Skyrizi should not be administered to patients with an allergy to risankizumab-rzaa or to any of the medication’s other ingredients.
Upper respiratory infections, headache, fatigue, injection site reactions, joint pain, stomach pain, anemia, back pain, fever, joint problems, urinary tract infection, and fungal skin infections are some of the side effects associated with Skyrizi medication; however, patients may experience other side effects. Contact your doctor immediately if you have side effects that bother you or won’t go away.
Skyrizi (risankizumab-rzaa). North Chicago, IL: AbbVie Inc.; 2022.